Adaptive Biotechnologies (ADPT) Aperçu de l'action
Adaptive Biotechnologies Corporation, une entreprise en phase de commercialisation, développe une plateforme de médecine immunitaire pour le diagnostic et le traitement de diverses maladies. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
ADPT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Adaptive Biotechnologies Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$13.54 |
| Plus haut sur 52 semaines | US$20.76 |
| Plus bas sur 52 semaines | US$8.50 |
| Bêta | 2.16 |
| Variation sur 1 mois | 5.86% |
| Variation sur 3 mois | -13.43% |
| Variation sur 1 an | 42.38% |
| Variation sur 3 ans | 108.63% |
| Variation sur 5 ans | -60.65% |
| Évolution depuis l'introduction en bourse | -66.40% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour de l'analyse • May 01
ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential
The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.
Mise à jour de l'analyse • Apr 16
ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows
Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.Mise à jour de l'analyse • Apr 02
ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential
Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.Mise à jour de l'analyse • Mar 19
ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows
Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.Mise à jour de l'analyse • Mar 04
ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside
The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.Mise à jour de l'analyse • Feb 18
ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential
Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.Mise à jour de l'analyse • Feb 03
ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside
Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.Mise à jour de l'analyse • Jan 20
ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside
Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.Mise à jour de l'analyse • Jan 05
ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside
Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.Seeking Alpha • Dec 26
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle
Summary Adaptive Biotechnologies Corporation maintains a Hold rating as MRD segment momentum is offset by competitive and valuation concerns. ADPT's Q3 top-line strength was driven by a one-time Genentech payment; ex-Genentech, MRD revenue grew 52% Y/Y, showing underlying operational progress. MRD segment achieved standalone cash flow positivity, but consolidated profitability remains elusive without normalization; FY25 MRD guidance was raised. DLBCL market share defense and workflow integration are critical as competition intensifies, making 2026 a pivotal "prove it" year for ADPT. Read the full article on Seeking AlphaMise à jour de l'analyse • Dec 15
ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside
Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.Mise à jour de l'analyse • Nov 30
ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing
Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.Mise à jour de l'analyse • Nov 16
ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing
Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.Mise à jour de l'analyse • Nov 01
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.Mise à jour de l'analyse • Oct 18
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.Article d'analyse • Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 31% gain in the...Mise à jour de l'analyse • Oct 04
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.Article d'analyse • Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d'analyse • Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce
Despite an already strong run, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have been powering on, with...Mise à jour de l'analyse • Aug 07
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.Article d'analyse • May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shareholders would be excited to see that the share price has had...Article d'analyse • May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d'analyse • Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
The Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) share price has done very well over the last month, posting an...
Nouvelle analyse • Mar 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.Article d'analyse • Feb 14
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 40% gain in the...Seeking Alpha • Nov 26
Adaptive Biotechnologies: Making Some Progress
Summary Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. Read the full article on Seeking AlphaArticle d'analyse • Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have had a really impressive month, gaining 25% after a...Article d'analyse • Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d'analyse • Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 27% gain in the...Article d'analyse • Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Life Sciences industry in the United States, you...Article d'analyse • May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d'analyse • Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares are down a...Rendement pour les actionnaires
| ADPT | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | -6.6% | -0.2% | 2.6% |
| 1Y | 42.4% | -1.1% | 26.2% |
Rendement vs Industrie: ADPT a dépassé le secteur US Life Sciences qui a rapporté -1.1 % au cours de l'année écoulée.
Rendement vs marché: ADPT a dépassé le marché US qui a rapporté 26.2 % au cours de l'année écoulée.
Volatilité des prix
| ADPT volatility | |
|---|---|
| ADPT Average Weekly Movement | 9.4% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: ADPT n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ADPT ( 9% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2009 | 624 | Chad Robins | www.adaptivebiotech.com |
Adaptive Biotechnologies Corporation, une entreprise au stade commercial, développe une plateforme de médecine immunitaire pour le diagnostic et le traitement de diverses maladies. L'entreprise propose une plateforme d'immunoséquençage qui combine un ensemble de techniques chimiques exclusives, la biologie computationnelle et l'apprentissage automatique pour générer des données immunomiques cliniques permettant de décoder le système immunitaire adaptatif. Elle propose le test de diagnostic clonoSEQ qui détecte et surveille le nombre restant de cellules cancéreuses présentes dans le corps d'un patient pendant et après le traitement, connu sous le nom de maladie résiduelle minimale (MRD).
Adaptive Biotechnologies Corporation Résumé des fondamentaux
| ADPT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.21b |
| Bénéfices(TTM) | -US$49.68m |
| Recettes(TTM) | US$295.41m |
7.3x
Ratio P/S-43.6x
Ratio P/ELe site ADPT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ADPT compte de résultat (TTM) | |
|---|---|
| Recettes | US$295.41m |
| Coût des recettes | US$166.28m |
| Marge brute | US$129.13m |
| Autres dépenses | US$178.81m |
| Les revenus | -US$49.68m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.31 |
| Marge brute | 43.71% |
| Marge bénéficiaire nette | -16.82% |
| Ratio dettes/capitaux propres | 58.2% |
Quelles ont été les performances à long terme de ADPT?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/11 16:05 |
| Cours de l'action en fin de journée | 2026/05/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Adaptive Biotechnologies Corporation est couverte par 13 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |